# Prelude Therapeutics Incorporated (PRLD) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.78, market value $302 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Prelude Therapeutics Incorporated reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 24.8×**. Each dollar of revenue is priced at 24.8×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.9×**. The shares trade at 2.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -11.0%** (5-yr avg -44.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -861.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -819.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -145.0%**. Return on equity is negative because earnings are negative.
- **Return on assets: -70.4%**. Each dollar of assets produces -70.4% of profit.

## Growth
- **Revenue growth (1 yr): 73.4%**. Revenue grew 73.4% over the last year.
- **EPS growth (1 yr): 23.2%**. Earnings per share rose 23.2%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 1.99** (quick 1.99). Current assets cover the next year's liabilities 1.99 times.
- **Altman Z-score: 1.26**. A Z-score of 1.26 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Prelude Therapeutics Incorporated does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 141.5%** (YTD 32.4%, 3-mo -12.5%). The shares are up 141.5% over twelve months including dividends.
- **From 52-week high: -44.7%** (222.3% above the low). Trading 45% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 48**. An RSI of 48 is neutral.
- **Beta (1 yr): 2.04** (volatility 195%). Beta of 2.04 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PRLD · Page: https://foliofundamentals.com/stocks/prld

Not investment advice.